Here are the 10-Q quarterly reports from DENTSPLY SIRONA Inc. (XRAY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XRAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XRAY filings page.
DENTSPLY SIRONA Inc. (XRAY) reported third-quarter 2026 net sales of $836 million, compared with $904 million a year earlier. Net loss attributable to the company was $2 million, versus a $427 million loss; for the first nine months, sales were $2.614 billion versus $2.719 billion and attributable net income was $25 million versus a $452 million loss.
Nine-month operating cash flow was $171 million, versus $134 million. An intercompany inventory estimate revision increased net income approximately $30 million, or $0.15 per basic and diluted share, for the three- and nine-month periods ended September 30, 2026; equivalent impacts are not expected in future periods. The 2026 restructuring plan is expected to carry approximately $60 million to $65 million in total non-recurring charges, the majority expensed and paid in cash in 2026 and 2027.
DENTSPLY SIRONA entered debt amendments on October 8, 2026, increasing maximum permitted leverage ratios, allowing additional EBITDA adjustments for the September and December 2026 quarters, and temporarily restricting certain new liens, subsidiary debt and restricted payments subject to exceptions; fees were approximately $4 million. For a proposed settlement subject to court approval, it recorded a $75 million liability and offsetting insurance receivable; insurers are to fund it, with no income-statement impact.
Dentsply Sirona (XRAY) reported Q3 2025 results with net sales of $904 million versus $951 million a year ago and an operating loss of $218 million. The quarter included $262 million of goodwill and intangible asset impairments, leading to a net loss of $427 million, or $2.14 per share.
Sales declined in the United States to $291 million from $374 million, while Europe rose to $382 million from $347 million. Segment mix showed Essential Dental Solutions at $357 million and Orthodontic and Implant Solutions at $205 million; Wellspect Healthcare increased to $83 million from $72 million.
Year to date, net sales were $2.719 billion versus $2.888 billion, with $497 million of impairments and a net loss of $452 million. Cash from operating activities was $134 million year to date, ending cash was $363 million. Long‑term debt was $2,017 million and current debt was $378 million. Goodwill decreased to $1,270 million from $1,597 million, and total equity was $1,478 million.